BioNTech (BNTX) News Today $111.93 -0.83 (-0.74%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period BioNTech SE (NASDAQ:BNTX) Receives $142.72 Average PT from BrokeragesJanuary 19 at 3:09 AM | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Sees Large Increase in Short InterestBioNTech SE (NASDAQ:BNTX - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,550,000 shares, a growth of 9.4% from the December 15th total of 2,330,000 shares. Based on an average daily volume of 806,600 shares, the short-interest ratio is presently 3.2 days.January 18 at 2:21 PM | marketbeat.comRetireful LLC Makes New $260,000 Investment in BioNTech SE (NASDAQ:BNTX)Retireful LLC acquired a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,278 shares of the company's stock, valued at approximately $260,000. Other institutional investors alJanuary 17 at 6:24 AM | marketbeat.comBioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from AnalystsBioNTech SE (NASDAQ:BNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seventeen analysts that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, thirteen have assigned aJanuary 16, 2025 | marketbeat.comGoldman Sachs Sticks to Their Buy Rating for BioNTech SE (BNTX)January 15, 2025 | markets.businessinsider.comTruist Financial Issues a Buy Rating on BioNTech SE (BNTX)January 15, 2025 | markets.businessinsider.comBioNTech SE: BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 14, 2025 | finanznachrichten.deBioNTech provides business and pipeline updatesJanuary 14, 2025 | markets.businessinsider.comBioNTech Unveils 2025 Strategic Priorities and Pipeline ProgressJanuary 14, 2025 | tipranks.comBioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 14, 2025 | globenewswire.comBioNTech (NASDAQ:BNTX) Coverage Initiated by Analysts at Truist FinancialJanuary 13, 2025 | americanbankingnews.comTruist Securities Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy RecommendationJanuary 10, 2025 | msn.comTruist Securities Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy RecommendationJanuary 10, 2025 | msn.comBioNTech (NASDAQ:BNTX) Now Covered by Analysts at Truist FinancialTruist Financial began coverage on BioNTech in a research report on Friday. They set a "buy" rating and a $172.00 target price on the stock.January 10, 2025 | marketbeat.comPromising Oncology Pipeline and Financial Strength Drive BioNTech’s Growth ProspectsJanuary 10, 2025 | markets.businessinsider.comBioNTech initiated with a Buy at TruistJanuary 10, 2025 | markets.businessinsider.comModerna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid SpikeJanuary 8, 2025 | yahoo.com3 Genomic Stocks Unlocking the Secrets of DNAJanuary 8, 2025 | stocknews.comFact Check: Edited BioNTech CEO clip resurfaces with false vaccine claimJanuary 7, 2025 | reuters.comBioNTech (NASDAQ:BNTX) Sees Strong Trading Volume - Time to Buy?BioNTech (NASDAQ:BNTX) Sees Large Volume Increase - Here's What HappenedJanuary 7, 2025 | marketbeat.comPrivate equity firms who hold 43% of BioNTech SE (NASDAQ:BNTX) gained 6.8%, institutions profited as wellJanuary 7, 2025 | uk.finance.yahoo.comBioNTech Sees Unusually Large Options Volume (NASDAQ:BNTX)BioNTech SE (NASDAQ:BNTX - Get Free Report) saw some unusual options trading on Tuesday. Stock traders bought 4,599 call options on the company. This represents an increase of approximately 58% compared to the typical volume of 2,906 call options.January 7, 2025 | marketbeat.com5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're RightJanuary 4, 2025 | fool.comFranklin Resources Inc. Sells 4,996 Shares of BioNTech SE (NASDAQ:BNTX)Franklin Resources Inc. reduced its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 59.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,384 shares of the company's stock after selling 4,99January 1, 2025 | marketbeat.comPenn to receive $467M under settlement with BioNTech over Covid-19 vaccine royaltiesDecember 30, 2024 | bizjournals.comNIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan StanleyDecember 30, 2024 | markets.businessinsider.comIf You’d Invested In These 5 Stocks Before the Last Inauguration Day, Here’s How Much They’d Be Worth NowDecember 29, 2024 | nz.finance.yahoo.comBioNTech to pay $791.5M in settlement agreement with the NIHDecember 27, 2024 | markets.businessinsider.comBioNTech to pay $467M in settlement agreement with University of PennsylvaniaDecember 27, 2024 | markets.businessinsider.comBioNTech Enters Into Settlements With U.S. Agency, UPenn Over COVID-19 Vaccine RoyaltiesDecember 27, 2024 | markets.businessinsider.comBioNTech Announces Settlement With National Institutes of Health, University of Pennsylvania Over Royalty ClaimsDecember 27, 2024 | msn.comBioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claimsDecember 27, 2024 | msn.comBioNTech Settles Royalty Dispute with University of PennsylvaniaDecember 27, 2024 | tipranks.comBioNTech Settles Royalty Dispute with NIH for $791.5 MillionDecember 27, 2024 | tipranks.comBioNTech enters settlement with US agency, UPenn over COVID vaccine royaltiesDecember 27, 2024 | reuters.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Vertex Pharmaceuticals (VRTX) and Ascendis Pharma (ASND)December 23, 2024 | markets.businessinsider.comBioNTech (NASDAQ:BNTX) Stock Price Down 1.3% - Time to Sell?BioNTech (NASDAQ:BNTX) Trading Down 1.3% - Should You Sell?December 18, 2024 | marketbeat.com3 No-Brainer Biotech Stocks to Buy With $200 Right NowDecember 18, 2024 | fool.comJ.P. Morgan Reaffirms Their Hold Rating on BioNTech SE (BNTX)December 17, 2024 | markets.businessinsider.comBioNTech (NASDAQ:BNTX) Shares Up 2.9% - Still a Buy?BioNTech (NASDAQ:BNTX) Trading 2.9% Higher - Here's What HappenedDecember 17, 2024 | marketbeat.comBarclays PLC Sells 50,453 Shares of BioNTech SE (NASDAQ:BNTX)Barclays PLC decreased its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 37.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 83,253 shares of the company's stock after selling 50,453 shares during the quarteDecember 17, 2024 | marketbeat.comBioNTech (NASDAQ:BNTX) Shares Down 2.3% - Time to Sell?BioNTech (NASDAQ:BNTX) Trading Down 2.3% - What's Next?December 16, 2024 | marketbeat.comExome Asset Management LLC Takes Position in BioNTech SE (NASDAQ:BNTX)Exome Asset Management LLC acquired a new position in BioNTech SE (NASDAQ:BNTX - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 34,552 shares of the company's stock, valued at approximately $4,104,000. BioNTech accountsDecember 14, 2024 | marketbeat.comY Intercept Hong Kong Ltd Invests $718,000 in BioNTech SE (NASDAQ:BNTX)Y Intercept Hong Kong Ltd purchased a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 6,046 shares of the company's stock, valued at approximately $718,000. A number of other institutional investoDecember 14, 2024 | marketbeat.comFDA Lifts Hold on BioNTech’s Key Cancer TrialDecember 13, 2024 | tipranks.comUS FDA lifts partial clinical hold on BioNTech cancer drug studyDecember 13, 2024 | reuters.comBioNTech (NASDAQ:BNTX) Stock Price Down 1.6% - Here's What HappenedBioNTech (NASDAQ:BNTX) Shares Down 1.6% - Here's WhyDecember 13, 2024 | marketbeat.comVestcor Inc Takes Position in BioNTech SE (NASDAQ:BNTX)Vestcor Inc bought a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,600 shares of the company's stock, valued at approximately $784,000. Several other hedDecember 13, 2024 | marketbeat.comCaptrust Financial Advisors Sells 8,909 Shares of BioNTech SE (NASDAQ:BNTX)Captrust Financial Advisors cut its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 70.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,678 shares of the company's stock after selling 8,909 shares during the quarter. CaptDecember 13, 2024 | marketbeat.comJefferies Keeps Their Buy Rating on BioNTech SE (BNTX)December 12, 2024 | markets.businessinsider.com Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address BNTX Media Mentions By Week BNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BNTX News Sentiment▼0.290.44▲Average Medical News Sentiment BNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BNTX Articles This Week▼1011▲BNTX Articles Average Week Get BioNTech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News Today Takeda Pharmaceutical News Today argenx News Today Teva Pharmaceutical Industries News Today BeiGene News Today Summit Therapeutics News Today Genmab A/S News Today Viatris News Today Intra-Cellular Therapies News Today Moderna News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BNTX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
